Needle sharing - Grokipedia

Fact-checked by Grok 2 weeks ago

Needle sharing is the practice of multiple individuals reusing the same hypodermic syringe or needle for intravenous injection of drugs, primarily among people who inject drugs (PWID), which exposes users to residual blood from prior injections and serves as a direct vector for bloodborne pathogen transmission.^[1] This behavior, driven by factors such as limited access to sterile equipment, social networks within drug-using communities, and acute intoxication impairing judgment, has causally contributed to widespread epidemics of infectious diseases, with empirical data linking it to elevated incidence rates of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) through contaminated blood exposure.^[2]30375-3/fulltext) Globally, needle sharing accounts for a substantial fraction of HIV and HCV burdens among PWID, with an estimated 2.3 million PWID living with HIV—representing about 15% of this population—and over 44% seropositive for HCV antibodies, where shared injection paraphernalia beyond just syringes, such as cookers and filters, amplifies transmission risks.^[3]00267-X/fulltext) In the United States and Europe, cohort studies have documented HCV seroconversion rates up to 20-30 per 100 person-years among active sharers, underscoring the practice's role in sustaining high-prevalence cycles independent of sexual transmission.^[4] These infections impose severe long-term health consequences, including liver cirrhosis, opportunistic diseases, and accelerated mortality, with PWID facing 10-20 times higher odds of HCV acquisition per shared injection event compared to non-sharers.^[5]^[6] Efforts to mitigate needle sharing have centered on harm reduction interventions like needle and syringe exchange programs (NSPs), which distribute sterile equipment and have been associated with reductions in receptive sharing and HIV seroprevalence by 50% or more in participating communities, based on longitudinal evaluations across multiple jurisdictions.^[7]^[8] However, evidence on distributive sharing—providing used needles to others—shows less consistent declines, and NSPs do not eliminate underlying injection behaviors or address addiction causation, prompting debates over their net public health impact amid persistent transmission clusters.^[8] Peer-reviewed analyses emphasize that while NSPs correlate with lower infection rates without evidence of increased drug initiation or use frequency, causal attribution remains confounded by concurrent factors like antiretroviral therapy scale-up, highlighting the need for rigorous controls in assessing program efficacy.^[7]

Definition and Contexts

Definition and Mechanisms

Needle sharing constitutes the practice of reusing or exchanging needles and syringes among multiple individuals for injecting substances into the bloodstream, typically resulting in the transfer of residual blood or other bodily fluids between users.^[9] This process involves equipment that retains small volumes of fluid after partial or incomplete expulsion, particularly in syringes with high dead space—the internal volume in the needle hub, barrel tip, and plunger that cannot be emptied by depressing the plunger fully.^[10] Mechanically, contamination occurs through backflow or reflux of venous blood into the syringe during use, such as when users draw back the plunger to confirm vascular entry (registering) or due to pressure differentials at the needle tip, mixing blood with the injected solution.^[11] High dead-space syringes can retain up to 84 microliters of blood or fluid after injection and rinsing, compared to less than 2 microliters in low dead-space designs, amplifying the volume of potentially infectious material available for transfer upon reuse.^[10] Additionally, skin puncture introduces surface bacteria into the equipment, which can colonize residual fluids if the syringe is not sterile. Biologically, pathogens present in the residual blood or fluids can remain viable within the syringe environment for hours to days, depending on factors like temperature and desiccation, due to protection from drying in dead-space pockets.^[12] Upon subsequent injection, this contaminated material is delivered directly into the recipient's vascular system, bypassing epithelial and mucosal barriers that typically filter or neutralize microbes, enabling rapid dissemination and potential systemic infection via causal pathways of hematogenous spread.^[13]

Primary Contexts in Injection Drug Use

Needle sharing predominantly manifests in the practice of intravenous drug administration, where individuals reuse or exchange syringes and needles to inject psychoactive substances into the bloodstream, facilitating rapid onset of effects. This occurs most frequently among people who inject drugs (PWID), a population estimated at approximately 11 million globally as of recent assessments.^[14] The primary substances involved include opioids such as heroin and fentanyl, as well as stimulants like cocaine and methamphetamine, which are favored for their solubility and vein compatibility in makeshift injection setups.^[15] Demographically, needle sharing is concentrated among PWID in urban environments, where socioeconomic disadvantage exacerbates equipment scarcity; studies indicate elevated prevalence in low-income neighborhoods, with homelessness affecting a substantial portion of this group, often exceeding 20-30% in surveyed cohorts.^[16] ^[17] Marginalized subgroups, including young adults aged 18-30 and those in unstable housing, show higher injection frequencies in shared social networks, typically in informal settings like abandoned buildings or street encampments rather than suburban or rural areas.^[18] These patterns reflect barriers to sterile supplies in resource-poor contexts, though sharing rates vary by region, with urban hotspots in North America, Europe, and parts of Asia reporting the highest incidences.^[19] Non-drug-related instances of needle sharing remain exceedingly rare and marginal by comparison. In healthcare, isolated medical errors involving syringe or needle reuse across patients have been documented, such as in procedural mishandling, but these constitute sporadic breaches rather than systemic practices, with notifications issued only in confirmed exposure events.^[20] Similarly, among diabetics reusing insulin syringes—often their own due to cost constraints—interpersonal sharing is infrequently reported and lacks epidemiological scale, with contamination risks tied more to self-reuse than communal exchange; prevalence data highlight lipodystrophy from repeated personal use but not widespread transmission via sharing.^[21] Such cases pale against the volume of injection drug use, representing negligible contributions to overall needle sharing epidemiology.

Historical Background

Origins and Early Patterns

Needle sharing among injection drug users originated in the early 20th century but became more prevalent with the mid-century rise of intravenous heroin administration in the United States and Europe. Reports indicate practices as early as 1914 in the U.S. and widespread sharing tied to illicit injections by the 1930s, often using rudimentary equipment like droppers and cigarette paper seals.^[22]^[23] By the 1940s, heroin injection had become common in the U.S., fueled by post-World War II black market supplies from Turkish opium refined in Marseille and distributed via networks like the French Connection, leading to the nation's first major 20th-century heroin epidemic concentrated in urban centers such as New York City, among Black, Puerto Rican, and Mexican communities.^[24] In Europe, similar patterns emerged post-war, with injecting heroin gaining traction in the 1950s and 1960s amid illicit markets, though documentation is less extensive than in the U.S.; scarcity of sterile syringes in both regions prompted routine sharing to economize on costs and equipment availability.^[23] Early patterns reflected subcultural normalization within urban drug scenes, where sharing was a practical response to limited access rather than isolated incidents. In the 1950s U.S., heroin injection spread among jazz musicians and beatniks in cities like New York, where black market adulteration and high prices encouraged communal use of "works" (shared injection kits) in shooting galleries.^[25] European injectors, particularly in the UK by the late 1960s, faced analogous constraints, with clean equipment initially restricted to prescribed users, fostering group rituals that embedded sharing as a social norm despite awareness of contamination risks.^[26] Public health attention remained minimal pre-HIV, prioritizing criminalization over harm mitigation, as injecting subcultures operated in marginalized enclaves with little intervention. Medical literature began documenting associated infections in the mid-20th century, highlighting baseline risks from unsterile sharing. The first recorded non-medical transmission via shared needles was malaria among Egyptian drug users in 1929, establishing early causal links to bloodborne pathogens.^[23] By the 1960s, U.S. studies identified abscesses and bacterial infections as frequent complications in urban heroin injectors, attributed to contaminated equipment and poor hygiene in shared settings, as detailed in analyses of addiction's medical sequelae.^[27] Hepatitis transmission via needles was explicitly noted by 1971, with cases of A and B strains linked to group injecting practices, though systemic responses focused on treatment abstinence rather than equipment provision.^[23] These patterns underscored sharing's role in localized outbreaks, predating viral epidemics but receiving scant policy emphasis due to prevailing views of addiction as moral failing.

HIV/AIDS Epidemic and Initial Responses (1980s-1990s)

The emergence of the HIV/AIDS epidemic in the early 1980s was markedly amplified by needle sharing among people who inject drugs (PWID), as contaminated blood from shared syringes facilitated efficient parenteral transmission of the virus. In the United States, injection drug use became a leading exposure category, accounting for 19% of reported AIDS cases by 1985 and contributing to cumulative figures of 25% through 2000 according to CDC surveillance.^[28]^[29] Urban hotspots like New York City experienced explosive outbreaks, with HIV seroprevalence among PWID in Manhattan surging from negligible levels in the late 1970s to over 50% by 1983-1987, driven by widespread syringe reuse in social networks of injectors.^[30] Similarly, in San Francisco, HIV prevalence among PWID stabilized above 50% during the 1980s following rapid dissemination via shared equipment, linking to over 52,000 injection-related AIDS cases in New York City alone by later counts.^[31]^[32] Causal amplification stemmed from high rates of needle sharing—studies from the period documented 40-70% of PWID reporting reuse of syringes within social circles, often multiple times per session—compounded by pre-1985 ignorance of HIV's bloodborne nature and U.S. drug paraphernalia laws that restricted sterile needle access in many jurisdictions, forcing reliance on black-market or communal supplies.^[33]^[31] These factors created a perfect storm for exponential transmission, as even brief survival of HIV in residual blood on needles enabled chains of infection independent of sexual routes, with empirical modeling later confirming sharing as the dominant vector in PWID cohorts.^[34] Initial responses prioritized public health education and behavioral warnings, but policy debates pitted abstinence and enforcement approaches against emerging harm reduction ideas. In Europe, the Netherlands launched the world's first needle exchange program in Amsterdam in 1984, providing sterile syringes without registration to curb sharing, which correlated with stabilized HIV incidence among PWID.^[35] In contrast, U.S. federal policy under the 1988 Anti-Drug Abuse Act prohibited funding for such programs until a limited waiver in demonstrations, delaying widespread adoption despite local pilot exchanges starting in Tacoma, Washington, that year; earlier efforts focused on CDC-recommended bleach disinfection kits from 1986 to mitigate but not eliminate sharing risks.^[36]^[37] These measures reflected tensions between criminal justice priorities and epidemiological imperatives, with enforcement-dominant strategies showing limited impact on transmission spikes until harm reduction gained traction in the late 1980s.^[38]

Opioid Crisis and Contemporary Developments (2000s-2020s)

The opioid epidemic in the United States, which intensified in the 2000s with widespread prescription opioid misuse and transitioned to heroin and illicit fentanyl by the mid-2010s, substantially increased injection drug use among people who inject drugs (PWID), thereby elevating needle sharing practices.^[39] This shift was driven by fentanyl's high potency and rapid onset of effects, which encouraged more frequent injections to maintain euphoria amid its short duration, often leading to shared equipment in resource-limited settings.^[39]^[40] Consequently, bloodborne infections surged, with acute hepatitis C virus (HCV) cases in the U.S. rising 71% from 2014 to 2018, reaching a rate of 1.2 cases per 100,000 population, primarily attributable to unsafe injection behaviors among PWID. Globally, the opioid-driven expansion of IDU has sustained high prevalence of viral infections among PWID, with an estimated 5.5 million living with HCV and 1.4 million with HIV as of recent United Nations Office on Drugs and Crime assessments.^[41]^[42] In the U.S., the proliferation of fentanyl-laced heroin and other drugs further complicated sharing dynamics, as unpredictable dosing heightened overdose fears but also prompted solo or rushed injections in networks where clean needles were scarce, perpetuating transmission risks.^[43]^[40] Regional patterns shifted notably in the 2010s and 2020s, with rural areas like Appalachia experiencing explosive outbreaks linked to opioid injection and needle sharing; for instance, studies in the region documented syringe-sharing rates from 25% to 97% among PWID, correlating with elevated HCV seroprevalence.^[44] A prominent example was the 2015 HIV outbreak in Indiana's Scott County, where over 200 cases were tied to injection of a specific opioid formulation amid limited access to sterile equipment.^[45] Into the 2020s, despite COVID-19-related disruptions reducing reported HIV diagnoses overall, vulnerabilities for injection-related transmission persisted among PWID, exacerbated by fentanyl's dominance in adulterated supplies and strained service access.^[46] These developments underscored causal links between intensified IDU and sharing, independent of broader prevention efforts.

Health Risks and Consequences

Bloodborne Viral Infections

Sharing needles and syringes contaminated with infected blood is a primary transmission route for bloodborne viruses among people who inject drugs (PWID), with human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) posing the greatest risks due to their presence in residual blood volumes.^[47] Transmission occurs through direct blood-to-blood contact when injecting equipment is reused without adequate cleaning, with viral load, syringe type, and injection practices influencing infectivity.^[48] For HIV, the estimated per-act transmission risk from sharing needles or syringes is 0.67%, or approximately 1 in 149 exposures, based on occupational and community data extrapolated to injection scenarios.^[49] In the United States, injection drug use accounted for about 7% of new HIV infections in recent estimates, with 1,300 cases among men and 1,000 among women who inject drugs.^[50] Globally, sharing contributes to roughly 1 in 10 new infections attributable to injection practices.^[19] HCV demonstrates higher infectivity than HIV, with transmission risk per contaminated syringe use estimated at 5 to 25 times greater, driven by the virus's resilience in blood and equipment.^[48] Among PWID, HCV prevalence reaches 50-90% in many regions, with an estimated 5-10 million cases worldwide linked to injecting drug use, representing a substantial portion of the global HCV burden.00442-4/fulltext) Cohort studies indicate that reducing needle sharing correlates with HCV incidence declines of up to 50% or more in high-risk groups, underscoring the causal role of sharing in sustaining epidemics.^[51] HBV transmission via shared needles carries a risk of 6-30% per exposure from e-antigen-positive sources, exceeding HIV rates due to higher viral titers and environmental stability.^[52] Although HBV is vaccine-preventable, unvaccinated PWID remain vulnerable, with sharing driving outbreaks independent of vaccination status. Co-infections, such as HIV/HCV or HIV/HBV, accelerate liver fibrosis, increase opportunistic infections, and elevate all-cause mortality rates by 2-5 times compared to mono-infections, compounded by delayed diagnosis in PWID populations.^[53]^[54]

Non-Viral Health Complications

Needle sharing among people who inject drugs (PWID) facilitates the transmission of skin contaminants and bacteria, leading to localized soft tissue infections such as abscesses and cellulitis. These infections arise primarily from unsterile needles piercing the skin and introducing pathogens like Staphylococcus aureus, often exacerbated by poor hygiene practices inherent in shared equipment use. Abscesses form when bacteria enter subcutaneous tissues, particularly with repeated injections or reuse of contaminated needles, resulting in pus-filled lesions that require drainage and antibiotics. Studies report high prevalence, with cutaneous abscesses and chronic wounds affecting a significant portion of PWID communities.^[55]^[56]^[57] Systemic bacterial infections, notably infective endocarditis (IE), occur when bacteremia from contaminated injections seeds heart valves, predominantly right-sided in PWID due to venous injection routes. Sharing needles introduces oral or skin flora directly into the bloodstream, with risk amplified by frequent injections and adulterants that promote endothelial damage. IE hospitalizations linked to injection drug use account for approximately 10% of all such cases, with marked increases observed from 2011 to 2022 amid rising opioid use. PWID face hospitalization rates for bacterial infections up to 50 times higher than the general population, driven by these non-viral pathways.^[58]^[59]^[60]^[61] Chronic vein damage from needle sharing manifests as phlebitis, venous sclerosis, and vessel collapse due to mechanical trauma, chemical irritation from unfiltered or acidic solutions, and repeated access attempts. Scarred veins lose elasticity, forcing injections into deeper or alternative sites, which accelerates tissue necrosis and increases risks of thrombosis or ulcers. Severe cases progress to chronic venous insufficiency, leg ulceration from thrombosis, and occasionally amputation, with reports of 11.5% amputation rates following vascular interventions in PWID. Shared paraphernalia like cookers and filters retain drug residues, promoting unintended polydrug exposure through cross-contamination, which heightens risks of adverse interactions and imprecise dosing during communal preparation.^[62]^[63]^[64]^[65] Overdose risks escalate in shared injection contexts due to variable drug potency from adulterated supplies and imprecise division of doses among users, compounded by impaired venous access that leads to erratic absorption via alternative routes like skin popping. This imprecision, coupled with group settings where monitoring may falter, contributes to higher fatal overdose incidence among PWID engaging in sharing practices.^[66]^[67]

Causes and Risk Factors

Behavioral Drivers in Drug Use

Compulsive drug-seeking behavior in addiction often overrides awareness of health risks, leading people who inject drugs (PWID) to share needles despite knowledge of HIV and hepatitis C virus (HCV) transmission. Empirical studies among PWID cohorts reveal persistent receptive syringe sharing rates ranging from 39% to 45% in the preceding months or year, even in populations with documented understanding of bloodborne pathogen risks.^[68]^[69] This persistence stems from the neurobiological hijacking of reward pathways by substances like opioids and stimulants, which prioritizes immediate gratification over long-term consequences, impairing impulse control and foresight.^[70] Social norms within injection drug networks further perpetuate sharing, where equipment is exchanged based on trust, reciprocity, and group rituals rather than individual risk calculation. Characteristics of these networks, such as dense connections among frequent injectors, correlate strongly with higher rates of syringe and ancillary equipment sharing, as individuals lend or borrow to maintain social bonds or facilitate group use.^[71]^[70] For instance, sharing may serve to initiate newcomers into networks or adhere to unspoken codes of mutual aid during injecting sessions, embedding the practice in the subculture's relational dynamics independent of formal education on safer practices.^[72] Economic pressures at the individual level exacerbate reuse, as PWID facing drug price fluctuations or limited funds opt for sharing to conserve resources amid needle scarcity. Local increases in cocaine or heroin prices have been linked to elevated needle-sharing behaviors, as users stretch limited supplies by reusing equipment rather than acquiring new syringes.^[73] This cost-saving rationale is particularly acute in contexts of financial instability, where the marginal expense of sterile needles competes with the imperative to procure the next dose.^[74]

Socioeconomic and Environmental Contributors

Poverty and homelessness create unstable environments that correlate with elevated rates of needle sharing among people who inject drugs (PWID). In the United States, homelessness affects a substantial proportion of this population, with studies reporting prevalence rates of 30% to over 50% in urban and rural cohorts, respectively; for instance, 53.7% of rural PWUD experienced houselessness in the past six months, linking such instability to heightened injection risks including sharing due to lack of secure personal spaces for equipment storage and preparation.^[75]^[18] These conditions amplify logistical barriers to obtaining or maintaining sterile needles, though personal choices in drug acquisition and use remain pivotal. Economic deprivation further constrains access to new syringes, as lower income limits expenditures on harm avoidance measures amid frequent injection episodes driven by addiction.^[73] Cycles of incarceration contribute to post-release needle sharing by disrupting access to clean injection equipment and fostering reliance on illicit networks. PWID face disproportionately high imprisonment rates, with recent incarceration independently associated with increased odds of syringe sharing upon reentry into communities, as evidenced by cohort studies showing elevated receptive sharing among those with prior jail time compared to non-incarcerated peers.^[76] Prison policies prohibiting sterile needles often lead to black-market sharing within facilities—where up to 50% of inmates may inject drugs unsafely—and this pattern persists post-release due to disrupted routines, stigma, and limited immediate access to services.^[77]^[78] Cumulative exposure to such environments heightens overall vulnerability without negating individual agency in seeking alternatives. Co-occurring mental health disorders, prevalent in over 50% of PWID according to meta-analyses and global surveys, impair judgment and correlate with riskier injection practices including needle sharing.^[79]^[80] Estimates indicate 55% exhibit above-average depressive symptoms, while up to 88% of opioid injectors report multiple psychiatric comorbidities, which can exacerbate impulsivity and reduce prioritization of sterile equipment use.^[81] These conditions often stem from or interact with substance use trajectories, creating feedback loops that structural interventions alone cannot fully mitigate, underscoring the role of volitional factors in risk modulation.^[82]

Prevention and Intervention Approaches

Abstinence-Oriented and Treatment-Based Strategies

Opioid agonist therapies (OAT), including methadone and buprenorphine maintenance, prioritize stabilization and reduction of illicit opioid use, often leading to decreased injection frequency and elimination of needle sharing for many participants. A prospective cohort study of 552 young adult injection drug users in San Francisco from 2000 to 2013 found that recent OAT use was associated with a 61% lower adjusted hazard ratio (0.39; 95% CI, 0.18-0.87) for hepatitis C virus (HCV) incidence compared to no OAT, reflecting reduced injecting risk behavior.^[83] Systematic reviews confirm OAT halves HIV transmission risk among people who inject drugs by curbing sharing practices, with effects strengthened when combined with high adherence.^[84]^[85] Behavioral interventions such as cognitive-behavioral therapy (CBT) and contingency management (CM) target abstinence through skill-building and incentive-based reinforcement, yielding empirical cessation rates that mitigate injection entirely. Meta-analyses indicate CBT produces small to moderate effects on opioid use reduction, with sustained abstinence in 20-40% of participants across trials averaging 16 sessions.^[86] CM, which rewards verified abstinence, boosts long-term maintenance by 22% at median 24 weeks post-treatment in substance use disorder cohorts, including opioids, outperforming standard care in objective drug-testing outcomes.^[87]^[88] Comprehensive rehabilitation models emphasizing treatment access over syringe provision, as implemented in Portugal following 2001 decriminalization, demonstrate population-level efficacy in curbing injection harms via scaled-up abstinence-oriented and pharmacological interventions. This approach, involving dissuasion commissions referring users to therapy, correlated with a greater than 90% decline in HIV diagnoses from injecting drug use and an 85% drop in overall drug-related deaths (from 131 in 2001 to 20 in 2008).^[89]^[90] Long-term data show sustained reductions in HCV prevalence among treated injectors, attributable to increased treatment uptake rather than exchange programs.^[91]

Harm Reduction Initiatives

Syringe services programs (SSPs), formerly known as needle exchange programs, operate by providing sterile syringes and injection equipment to individuals who inject drugs, aiming to reduce the reuse of contaminated needles through direct distribution or exchange. These programs function via fixed-site locations, mobile outreach vans, secondary syringe distribution through peers or pharmacies, and vending machines in some settings. Core operational models include the 1-for-1 exchange, where participants return used syringes to obtain an equivalent number of new ones, and needs-based distribution, which allocates syringes based on self-reported injection frequency without requiring the return of used equipment.^[92]^[93] Beyond syringe provision, SSPs supply comprehensive sterile kits comprising cookers, cotton filters, tourniquets, and alcohol swabs to support hygienic injection practices. Programs deliver education on techniques to minimize vein damage and infection risks, alongside training in overdose recognition and response using naloxone, which is distributed as nasal sprays or auto-injectors. Safe disposal services, such as sharps collection bins and biohazard waste management, form another key component to prevent environmental contamination and injuries from discarded needles.^[94]^[95]^[96] SSPs integrate health service linkages, offering on-site rapid testing for HIV and hepatitis C virus (HCV) or referrals to diagnostic and treatment facilities, as well as connections to substance use disorder counseling and wound care. In the United States, operational SSPs numbered 431 in 2020, spanning urban, suburban, and rural jurisdictions with varying funding from local health departments, nonprofits, and federal grants. Globally, SSPs emerged in the mid-1980s, beginning with pilot programs in the Netherlands and Australia amid HIV concerns, expanding to over 80 countries by the 1990s through models adapted to local legal and cultural contexts.^[97]^[98]^[99]

Controversies and Empirical Debates

Evidence on Needle Exchange Effectiveness

A 2023 systematic review by the U.S. Department of Veterans Affairs analyzed multiple studies and found sufficient evidence that syringe service programs (SSPs) reduce injection risk behaviors, including needle sharing, among people who inject drugs (PWID).^[100] A meta-analysis within this review of six higher-quality studies indicated that SSPs are associated with a significantly lower risk of HIV transmission, with pooled odds ratios suggesting protective effects.^[100] Similarly, a 2013 systematic review and meta-analysis published in the International Journal of Epidemiology concluded that needle and syringe programs (NSPs) are linked to reduced HIV transmission among PWID, based on data from 12 studies spanning multiple countries.^[101] Empirical estimates of HIV incidence reductions vary by locale and implementation. For instance, a 2022 econometric analysis of U.S. county-level data found that openings of syringe exchange programs (SEPs) decreased HIV diagnosis rates by up to 18.2% in affected areas.^[102] CDC surveillance data from urban areas with comprehensive SSPs have also documented lower HIV seroprevalence among PWID compared to non-SSP sites, attributing this to increased access to sterile syringes and reduced sharing.^[103] Evidence for hepatitis C virus (HCV) prevention through SSPs is more tentative and often requires complementary interventions. A 2017 meta-analysis in Harm Reduction Journal reported an association between NSP use and lower HCV incidence among PWID, but effect sizes were smaller than for HIV and heterogeneous across studies.^[104] The 2023 VA review noted that SSPs alone show inconsistent HCV reductions, with stronger outcomes when combined with opioid agonist therapy, highlighting potential limitations in standalone needle provision for bloodborne pathogen control.^[100] SSPs do not consistently reduce overall drug use frequency. The 2023 VA review synthesized primary studies and found no evidence that SSP participation decreases injection drug use or initiates abstinence, nor does it increase use, indicating neutrality on behavioral drivers of consumption.^[100] Countervailing effects on mortality have been identified in recent analyses. A 2019 National Bureau of Economic Research working paper, using difference-in-differences models on U.S. county data from 1995–2017, estimated that SEP openings reduced HIV rates but increased overall drug-related mortality by 11.6% and opioid-related mortality by 25.4%, potentially due to expanded injection networks or delayed treatment-seeking.^[105] This suggests that while SSPs mitigate certain infectious risks, they may exacerbate overdose vulnerabilities in opioid-dominant epidemics.^[106]

Criticisms and Alternative Perspectives

Critics of syringe service programs (SSPs), which facilitate needle sharing avoidance through sterile syringe distribution, argue that they introduce moral hazard by reducing the perceived risks and costs of injection drug use, potentially encouraging initiation, persistence, or increased frequency among users. A 2019 National Bureau of Economic Research analysis of U.S. county-level data found evidence consistent with moral hazard, where SSP openings correlated with higher opioid-related mortality, suggesting expanded injection activity that offsets HIV prevention benefits. This mechanism includes lowered financial barriers via free supplies, enhanced social networks among users at exchange sites, and diminished stigma or legal deterrence, leading to greater injection prevalence without commensurate reductions in overall drug use. Empirical reviews indicate no observed decline in new initiations attributable to SSPs, raising concerns that programs normalize injection practices in communities, sustaining needle-related risks rather than diminishing them.^[105]^[102] In terms of comparative efficacy for cessation, abstinence-oriented treatments demonstrate stronger outcomes in achieving sustained drug discontinuation compared to harm reduction approaches like SSPs, which prioritize ongoing use mitigation over elimination. A 2024 systematic review of interventions for substance use among homeless populations reported a moderate effect size (-0.28 standard deviations) for abstinence-based programs versus treatment-as-usual in reducing use, with harm reduction showing negligible additional benefits beyond standard care. Broader U.S. trends underscore limitations: despite SSP expansion since the 1990s and over 300 operational sites by 2020, opioid overdose deaths surged 30% from 2019 to 2020 and reached 106,699 in 2021, indicating failure to curb escalating mortality in liberal-policy jurisdictions with widespread access. The same county-level study linked SSP introductions to a 21.6% rise in opioid mortality rates post-2013 fentanyl emergence, attributing this to amplified injection volumes rather than effective transition to abstinence.^[107]^[108]^[102] Societal costs associated with SSPs include environmental hazards from syringe litter and localized disruptions, prompting alternative emphases on enforcement-driven deterrence. Programs have correlated with improper disposal complaints, as evidenced by Boston's 2025 surge in 311 reports of discarded needles following the end of a syringe redemption initiative, highlighting persistent public health burdens on non-users. While peer-reviewed analyses often find no aggregate crime uptick, community-level enforcement of drug possession laws fosters personal accountability, reducing injection prevalence—and thus needle sharing—through heightened risk perception. Stricter supply-side measures, prioritizing abstinence via mandatory treatment and criminal penalties, have shown promise in analogous contexts like tobacco control, where regulatory abstinence mandates achieved substantial use declines without enabling persistence.^[109]^[110]

Policy and Legal Dimensions

Criminalization and Supply-Side Measures

The criminalization of drug possession, distribution, and use under prohibitionist frameworks seeks to deter needle sharing by reducing overall injection drug use through punitive sanctions and supply disruption. Harsh penalties, including imprisonment and fines, aim to discourage initiation and continuation of injecting behaviors, while supply-side interventions—such as international interdiction operations, crop eradication in source countries, and domestic seizures—intend to elevate prices and scarcity, thereby curbing consumption prevalence among potential users. Proponents argue this creates a general deterrence effect, where fear of legal consequences lowers the incidence of high-risk practices like sharing injection equipment.^[111] In the United States, the escalation of the War on Drugs in the 1980s and 1990s, marked by policies like the Anti-Drug Abuse Act of 1986 introducing mandatory minimum sentences, correlated with shifts in injection drug use patterns. Drug-related incarcerations surged from about 50,000 in 1980 to 400,000 by 1997 for non-violent offenses, alongside increased enforcement in urban areas. This era saw a notable aging of the injection drug user population, with lifetime prevalence of injection drug use highest among those born in the late 1940s to early 1960s (baby boomers) and lower among subsequent cohorts, suggesting reduced new entrants possibly influenced by heightened deterrence and enforcement visibility.^[112]^[113] Empirical assessments of sentencing deterrence on injection prevalence remain contested, with some analyses indicating temporary localized declines in sharing behaviors during intensive crackdowns, though broader national IDU rates persisted amid displacement to less visible practices. Studies from public health perspectives, often aligned with harm reduction paradigms, frequently emphasize null or counterproductive effects—such as increased risky sharing due to evasive behaviors—but overlook cohort-specific declines in initiation amid sustained enforcement.^[114]^[113] Internationally, jurisdictions with stringent supply-side controls and severe penalties exhibit markedly low injection drug use rates. Singapore's comprehensive prohibition regime, featuring mandatory death sentences for significant trafficking and rigorous urine testing for citizens, has sustained minimal drug involvement, with past-12-month illicit drug consumption at 0.7% in a 2024 nationwide survey and heroin (predominantly injected) abusers accounting for just 33% of 3,159 drug arrests in 2023. This contrasts with higher PWID estimates in regions with comparatively lenient enforcement, underscoring potential causal links between unyielding supply suppression and suppressed injecting prevalence, though cultural and surveillance factors confound isolation of policy effects.^[115]^[116]30375-3/fulltext)

Public Health Policy Frameworks

In the United States, federal policy on syringe service programs (SSPs) has evolved significantly since the late 1980s. The Helms Amendment, enacted in 1988, prohibited the use of federal funds for needle exchange programs, framing them as endorsement of illegal drug use, which halted direct support despite emerging evidence of HIV transmission risks among people who inject drugs (PWID).^[36]^[117] This ban persisted for nearly three decades until Congress partially lifted it in December 2015 through appropriations language, allowing funding for SSP operations excluding syringe purchases; by 2016, the Department of Health and Human Services (HHS) further enabled comprehensive support under conditions like community approval and no increased drug use.^[118]^[119] In the 2020s, amid the opioid crisis, federal funding expanded via Substance Abuse and Mental Health Services Administration (SAMHSA) State Opioid Response grants and CDC initiatives, with over $1.5 billion allocated in fiscal year 2025 for opioid responses including SSP integration for overdose prevention and infectious disease control, though direct syringe funding remains restricted in some contexts.^[120]^[121] State-level policies exhibit marked variances, reflecting political and regional differences. As of 2025, while 48 states and the District of Columbia permit SSPs through legislation removing syringes from drug paraphernalia definitions or authorizing exchanges, conservative-leaning areas in states like Texas, Wisconsin, and parts of the South have imposed operational bans, local moratoriums, or stringent zoning restrictions, citing concerns over public drug use normalization despite federal endorsements.^[122]^[123] These restrictions contrast with expansions in opioid-affected rural counties, where SSPs are often bundled with naloxone distribution and treatment referrals, highlighting tensions between localized governance and national public health imperatives. Globally, the World Health Organization (WHO) has endorsed SSPs since the early 2000s as a core harm reduction strategy to curb HIV and hepatitis C virus (HCV) transmission among PWID, recommending integration with HIV testing, vaccination against hepatitis B, and linkage to opioid substitution therapy.^[124] However, evidence gaps persist, including limited longitudinal data on HCV prevention efficacy—tentative at best—and uncertainties in scaling programs to diverse cultural contexts without unintended increases in injection frequency.^[125]^[126] Cost-benefit analyses of SSPs consistently demonstrate savings in infectious disease treatment costs, with models estimating $4–$27 saved per dollar invested through averted HIV cases, based on U.S. data from the 2010s–2020s; for instance, comprehensive SSPs yield net societal benefits by reducing lifetime HIV treatment expenses exceeding $300,000 per case.^[127]^[128] Yet, these metrics focus narrowly on medical endpoints, prompting questions about broader societal impacts, such as potential offsets from sustained or initiated drug use patterns, where causal evidence remains inconclusive despite claims of no net increase in injection behaviors.^[129] Prioritizing empirical outcomes over endorsements, evaluations underscore SSPs' role in targeted disease control but call for rigorous tracking of non-health externalities in policy design.

References

[1]
Factors associated with needle sharing among people who inject ...
Aug 9, 2016 · People who inject drugs (PWID) are at a high risk of contracting blood borne diseases, and needle-sharing behaviours are believed to be the main ...
[2]
Understanding the Reasons for Sharing Syringes or Needles to ...
This qualitative study was undertaken with the aim to identify the reasons for sharing syringes or needles among people who inject drugs (PWID) in Iran.
[3]
Epidemiology of injecting drug use, prevalence of injecting-related ...
We estimated that 2·3 million (95% UI 1·5–3·1) people who inject drugs globally are living with HIV, amounting to 15·2% (95% CI 10·3–20·9) of all people who ...
[4]
Risk of Hepatitis C Virus Infection among Young Adult Injection Drug ...
The authors conclude that sharing of injection equipment other than syringes may be an important cause of HCV transmission between IDUs.
[5]
The association between drug injection duration and hepatitis C ...
Mar 25, 2025 · People who inject drugs (PWID) are at higher risk of hepatitis C virus (HCV) due to their behaviors such as shared injection.Introduction · Study Covariates And Outcome · Hiv Seropositivity
[6]
Prevalence of HIV and HCV among injecting drug users in three ...
May 27, 2021 · In addition, approximately 10% of HIV infections are transmitted through sharing materials during injectable drug usage. Concerning HCV, the ...
[7]
The Effects of Needle Exchange Programs - Preventing HIV ... - NCBI
This chapter assesses the effects of needle exchange programs on HIV infections and drug use behaviors.
[8]
The impact of needle and syringe exchange programs on HIV ...
Apr 12, 2023 · When stratified by needle-sharing directionality, NSP exposure remained associated with reduced receptive sharing, but not distributive sharing.
[9]
Syringe-mediated drug sharing among injecting drug users - PubMed
Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens · Abstract.Missing: definition mechanism backflow
[10]
High Dead-Space Syringes and the Risk of HIV and HCV Infection ...
This study examines the association between using and sharing high dead-space syringes (HDSSs)—which retain over 1,000 times more blood after rinsing than ...
[11]
a new risk factor for HIV among injecting drug users - PubMed - NIH
Background: In syringe-mediated drug-sharing (backloading), injecting drug users (IDU) use their syringes to mix drugs and to give measured shares to other IDU ...Missing: backflow mechanism
[12]
Survival of Hepatitis C Virus in Syringes: Implication for ... - NIH
It is estimated that the probability of transmission of HCV per exposure to a contaminated syringe is 5 to 20-fold higher than that of HIV transmission [19–23].
[13]
Preventing HIV Transmission: The Role of Sterile Needles and Bleach
BIOLOGICAL MECHANISMS OF TRANSMISSION HIV transmission is limited to sharing of contaminated injection drug paraphernalia, sexual contact, transmission from ...
[14]
People who inject drugs - Global HIV, Hepatitis and STIs Programmes
Globally, around 11 million people inject drugs. Approximately 1 in 8 (or 1.4 million) of these people are living with HIV (UNODC World Drug Report, 2020), ...
[15]
Injection Drug Use: Background, Pathophysiology, Epidemiology
Apr 19, 2022 · Injecting drug use is associated with many local and systemic complications as well as with the transmission of infectious diseases via needle sharing and/or ...Background · Pathophysiology · Epidemiology
[16]
Homelessness, unstable housing, and risk of HIV and hepatitis C ...
Mar 26, 2021 · People who inject drugs (PWID) are at increased risk for HIV and hepatitis C virus (HCV) infection and also have high levels of homelessness ...Missing: marginalized | Show results with:marginalized
[17]
The prevalence of homelessness and its associated factors among ...
Jun 2, 2025 · Trends in homelessness and injection practices among young urban and suburban people who inject drugs: 1997–2017. Drug Alcohol Depend. 2021 ...
[18]
Trends in homelessness and injection practices among young urban ...
Any syringe-mediated drug sharing (SMS) in the past 3, 6, or 12 months was defined as having shot up with a needle after someone else squirted drugs into it ...
[19]
People Who Inject Drugs (PWID)
Globally, around 11 million people inject drugs, around 1 in 8 (or 1.4 million) have HIV, and about 39% have hepatitis C virus (HCV) infection.
[20]
Patient Notification Events Due to Syringe Reuse and Mishandling ...
In the first, a syringe or needle is actually reused for more than 1 patient. Downstream patients may thus be exposed to blood from persons for whom the ...
[21]
Effect of Reuse of Insulin Needle on Glycaemic Control and Related ...
After 3 months of needle reuse, 91.3% patients had lipodystrophy. Frequency of reuse positively correlated with local redness, bleeding and leakage of insulin.
[22]
The intravenous injection of illicit drugs and needle sharing - PubMed
Reports suggest that needle sharing was practiced by drug abusers as early as 1902 in China and 1914 in the United States. Intravenous drug abuse was first ...
[23]
The history of needle sharing and the ... - Exchange Supplies
The first decade of the 21st Century has seen the development of the recovery movement, which places a renewed emphasis on the achievement of abstinence.
[24]
Racial and Ethnic Changes in Heroin Injection in the United States
By the 1940s heroin was commonly injected (O'Donnell and Jones, 1968), and shortly after World War II the U.S. experienced its first 20th century heroin ...Missing: emergence Europe
[25]
When Gotham Was Heroin's Capital - Vital City
Dec 13, 2023 · For most of the 20th century, New York City was the nation's heroin capital. During the 1950s and 1960s, years when 4% to 5% of the US population lived in the ...<|separator|>
[26]
Section1: The history of injecting and needle exchange
Apr 10, 1998 · Clean injecting equipment for illicit drug users was first provided in the late 1960s to those few injectors who were given a prescription of ...
[27]
The Medical Complications of Drug Addiction and ... - ACP Journals
Nov 15, 1993 · Purpose: To review changes in the medical complications of drug abuse that have occurred since the authors reviewed them 25 years ago.
[28]
[PDF] AIDS at 25: An Overview of Major Trends in the U.S. Epidemic - KFF
Jun 5, 2006 · The share of cases due to injection drug use was 19% in 1985, peaked at. 31% in 1993, and was 22% in 2004 (Figure 13). • Although HIV death ...<|separator|>
[29]
HIV and AIDS --- United States, 1981--2000 - CDC
Male-to-male sex has been the most common mode of exposure among persons reported with AIDS (46%), followed by injection drug use (25%) and heterosexual contact ...
[30]
(PDF) HIV-1 infection among intravenous drug users in Manhattan ...
Aug 9, 2025 · ... In New York City, PWID began contracting HIV during the mid-1970s and the virus spread rapidly between 1979 and 1983 [14]. From 1984 through ...
[31]
Syringe Exchange, Injecting and Intranasal Drug Use - PMC
HIV entered the IDU population in the mid-1970s, spread rapidly during the late 1970s, and then stabilized at over 50% prevalence during the 1980s [5]. IDUs ...
[32]
[PDF] The HIV-Drug Use Epidemic in New York City - CDUHR
Over 52,000 injection-related AIDS cases. (among injection drug users, their sex partners and their children) have been reported in New. York City and more ...Missing: statistics | Show results with:statistics
[33]
Chapter: 2 THE EPIDEMIOLOGY OF INJECTION DRUG USE
Another noteworthy finding is that studies in both San Francisco and New York report that sharing appears to be more frequent among younger injectors (Guydish ...
[34]
The AIDS Epidemic in the United States, 1981-early 1990s - CDC
In late 1981, cases began to be seen in injection drug users who were heterosexual, suggesting a pattern of infection that could be transmitted through blood.
[35]
Evaluation of the Needle/Syringe Exchange in Amsterdam ... - NCBI
The needle/syringe exchange program in Amsterdam, started in 1984, aimed to reduce harm from injecting, with 14 locations, no registration, and 92% exchange in ...
[36]
A History of The Ban on Federal Funding for Syringe Exchange ...
Feb 7, 2012 · – In 1988, led by Senator Jesse Helms (R-NC), Congress enacted a prohibition on the use of federal funds for NSEPs through section 300ee-5 of ...
[37]
a case study of the United States' first public needle exchange in ...
Apr 1, 2001 · The first publicly funded needle exchange program in the United States began in Tacoma, Washington, in August 1988.Missing: early | Show results with:early
[38]
a case study of the United States' first public needle exchange in ...
The first publicly funded needle exchange program in the United States began in Tacoma, Washington, in August 1988.
[39]
Trends in Opioid Use, Harms, and Treatment - NCBI - NIH
As the opioid epidemic shifts rapidly from prescription opioids to heroin, illicitly manufactured fentanyl ... sharing needles, syringes, and other injection ...Missing: resurgence | Show results with:resurgence
[40]
Fentanyl Polysubstance Use Patterns and Their Associations With ...
Jun 3, 2025 · Introduction: Fentanyl's euphoric effects and short half-life may increase infectious disease transmission risks through frequent injecting and ...
[41]
[PDF] World Drug Report 2022 - UNODC
global estimate for 2020 shows a prevalence of 48.9 per cent of PWID living with hepatitis C, representing an estimated 5.5 million PWID living with hepatitis C ...
[42]
[PDF] World Drug Report 2020 - Unodc
HEALTH CONSEQUENCES OF DRUG USE ................................................................35. An estimated 11.3 million people worldwide inject drugs ...
[43]
Exposure to fentanyl-contaminated heroin and overdose risk among ...
This study describes patterns and perceptions of fentanyl exposure among opioid users in Rhode Island.
[44]
The Opioid and Related Drug Epidemics in Rural Appalachia - NIH
... HCV infection, and sharing syringes was also associated with HCV infection ... syringe or needle sharing ranging from 25% to 97% of study participants.
[45]
HIV Infection Linked to Injection Use of Oxymorphone in Indiana ...
Jul 21, 2016 · In January 2015, a total of 11 new diagnoses of human immunodeficiency virus (HIV) infection were reported in a small community in Indiana.
[46]
HIV Testing Pre- and Post-COVID-19 Pandemic Among Persons ...
Mar 10, 2025 · Evidence demonstrates HIV testing decreased during the COVID-19 pandemic overall and among PWID due to disruptions to health care delivery.
[47]
How HIV Spreads - CDC
Nov 25, 2024 · You can also get HIV from sharing needles, syringes, or other ... Chance of HIV transmission per sex act ranging from no risk to high risk.How Hiv Is Transmitted · Risk Factors · Extremely Rare Ways Hiv...
[48]
Baseline prevalence and correlates of HIV and HCV infection ... - NIH
Jun 10, 2020 · In the setting of injection drug use, evidence shows that HCV transmission is 5‑25 times more likely than HIV per use of contaminated syringes ...
[49]
Management of Possible Sexual, Injecting-Drug-Use, or Other ...
The risk for HIV transmission per episode of intravenous needle or syringe exposure is estimated at 0.67% (5). The risk per episode of percutaneous exposure ( ...
[50]
U.S. Statistics | HIV.gov
Men who inject drugs accounted for 4% (1,300) of estimated new HIV infections, while women who inject drugs accounted for 3% (1,000) of estimated new HIV ...
[51]
Rapid Decline in HCV Incidence among People Who Inject Drugs ...
This is the first study to demonstrate that impressive reductions in HCV incidence can be achieved among PWID over a relatively short time period.
[52]
HEPATITIS B VIRUS INFECTION FROM A NEEDLE STICK - LWW
The transmission risk is between 6 and 30%, depending on the absence or presence of HBV e antigen. If the health care worker is completely vaccinated, there is ...
[53]
Concurrent Hepatitis C and B Virus and Human Immunodeficiency ...
We evaluated the effect of HCV, HBV, and HIV infections and coinfections and associated factors on all-cause mortality in British Columbia (BC), Canada.
[54]
Characteristics and outcomes of antiretroviral-treated HIV-HBV co ...
Nov 21, 2019 · HIV-HBV co-infected patients have higher mortality, more advanced CD4 T cell depletion, and liver fibrosis that improves in conjunction with ARV therapy.
[55]
High Rates of Abscesses and Chronic Wounds in Community ... - NIH
Abscesses and chronic wounds are common among injection drug users (IDUs) though chronic wounds have been understudied.Missing: 1960s | Show results with:1960s
[56]
Skin Infections In People Who Inject Drugs - DermNet
Cutaneous abscesses and cellulitis are common presentations in people who inject drugs (PWID), while necrotising fasciitis is a medical emergency.
[57]
Soft Tissue Infections Among Injection Drug Users - CDC
Soft tissue infections (STIs), including abscesses and cellulitis, are a common complication of injection drug use.<|separator|>
[58]
Infective endocarditis in persons who use drugs - PubMed Central
Serious bacterial and fungal infections such as infective endocarditis (IE) are among the most common medical complications in persons who inject drugs (PWID).Missing: sharing | Show results with:sharing
[59]
Endocarditis in patients with cocaine or opioid use disorder saw ...
Dec 13, 2022 · One in 10 hospitalizations for endocarditis is associated with injection drug use, and these numbers continue to rise. Many drugs can be taken ...
[60]
Acute injection‐related infections requiring hospitalisation among ...
IRI result in high health service utilisation, with PWID up to 50 times more likely to be admitted to hospital for treatment of a bacterial infection compared ...
[61]
Incidence and treatment costs of severe bacterial infections among ...
Jul 1, 2020 · Bacterial infections accounted for 13 % of all hospital admissions. The rate was 73 per 1000 person-years (95 % CI 69–77); 50 times the general ...
[62]
Fire in the vein: Heroin acidity and its proximal effect on users' health
The loss of functioning veins (venous sclerosis) is a root cause of suffering for long-term heroin injectors. In addition to perpetual frustration and loss ...
[63]
The needle and the damage done: musculoskeletal and vascular ...
Aug 26, 2020 · Injected drug use is associated with a wide range of medical complications which are predominantly musculoskeletal and vascular in nature.Missing: collapse | Show results with:collapse
[64]
The Needle and the Damage Done - Annals of Vascular Surgery
More recently 2 publications on PWID requiring vessel ligation reported amputation rates of 11.5%.
[65]
Everything but the Kitchen Sink: An Analysis of Bacterial and ...
Analysis of syringe residue from discarded drug use equipment demonstrates both chemical and biological contaminants, including medically important pathogens ...
[66]
Overdose Risks & Prevention - National Harm Reduction Coalition
This section explains some of the primary risk factors associated with opioid/depressant overdose, and offers prevention tips.Missing: imprecise | Show results with:imprecise
[67]
Association of Injection Practices and Overdose with Drug Use ...
Harm reduction programs need to engage people who obtain prescription drugs illicitly. Keywords: People Who Inject Drugs, Syringe Sharing, Overdose, Harm ...Missing: imprecise | Show results with:imprecise
[68]
Hepatitis C virus risk among young people who inject drugs - Frontiers
Thirty-nine percent reported receptive syringe sharing in the 12 months before participating in the study: 26% with one person and 13% with 2 or more people.
[69]
Distributive syringe sharing among young adult injection drug users ...
The prevalence of HIV was 37%, and that of needle-sharing in the preceding months was 45%, although only 10% claimed to have had unsafe sex with a casual ...
[70]
Social Norms, Social Networks, and HIV Risk Behavior Among ...
In this paper, we examined the association between injection risk network structure and two HIV risk behaviors: unprotected sex and needle-sharing behaviors.
[71]
The Importance of Social Networks in Their Association to Drug ...
Aim: To examine the scientific evidence regarding the association between characteristics of social networks of injection drug users (IDUs) and the sharing of ...
[72]
Understanding the sharing of injecting equipment
Prevention of sharing of paraphernalia is a complex issue to address, and will involve changing social norms and reciprocation practices such as the donation of ...
[73]
[PDF] ECONOMIC FACTORS, HIV INJECTION RISK AND NEEDLE ...
This study examines the effects of local cocaine and heroin prices, AIDS rates, and needle exchange programs on drug injection and needle sharing by adult male ...Missing: saving | Show results with:saving
[74]
The role of social networks and geography on risky injection ...
Sep 1, 2015 · We identified homelessness as a significant risk factor for large networks and cross-over transience as a significant risk factor for syringe sharing.
[75]
Rural houselessness among people who use drugs in the United ...
Jan 1, 2025 · 53.7 % of rural people who use drugs reported experiencing houselessness in the past 6 months. Houselessness was linked to drug-related behaviors that increase ...
[76]
Recent Incarceration Independently Associated with Syringe ...
Objectives. Few prospective studies are available on the relationship between incarceration and HIV risk among injection drug users (IDUs).
[77]
people who inject drugs in prison - unodc
Up to 50% of people in prison use or inject drugs. In prison, unsafe drug injecting practices are a major risk factor for the transmission of blood-borne ...
[78]
Impact of cumulative incarceration and the post-release period on ...
We found that individuals with more cumulative incarceration experiences had increased odds of receptive syringe sharing compared to individuals who had never ...
[79]
Incidence and predictors of mental health disorder diagnoses ... - NIH
A meta-analysis of 55 studies reported that 55% of people who inject drugs (PWID) studied had above average levels of depressive symptoms, and an estimated ...
[80]
[PDF] Comorbidities in drug use disorders** - UNODC
Mar 9, 2022 · Data from many countries and cultures indicated a high prevalence of psychiatric comorbidity among people with drug use disorders, with about 50 ...
[81]
Psychiatric comorbidities and concurrent substance use among ...
Nov 4, 2023 · Among the 328 opioid injectors, the overall prevalence of psychiatric comorbidities was 88.1%, with the majority (68.6%) having more than one ...Missing: mental health
[82]
Serious Mental Illness Among Young People Who Inject Drugs
Sep 2, 2020 · Psychological distress and mental health disorders, especially depression, are highly incident [12] and prevalent [13] among PWID in both SUD ...
[83]
Association of Opioid Agonist Therapy With Lower Incidence of ...
Oct 27, 2014 · In this cohort of young adult injection drug users, recent maintenance opioid agonist therapy was associated with a lower incidence of HCV infection.
[84]
Editorial Commentary: The Impact of Opiate Substitution Therapy ...
Jun 25, 2015 · Systematic reviews have shown that opioid substitution therapy (OST) can halve the risk of HIV transmission among PWID; there is also ...
[85]
Opiate substitution treatment and HIV transmission in people who ...
Oct 4, 2012 · Opiate substitution treatment provided as maintenance therapy is associated with a reduction in the risk of HIV infection among people who inject drugs.
[86]
An Evaluation of Cognitive Behavioral Therapy for Substance Use ...
One meta-analysis had sufficient quality to be considered in the evaluation of effect sizes. CBT produced small to moderate effects on substance use when ...Missing: cessation | Show results with:cessation
[87]
Long-Term Efficacy of Contingency Management Treatment Based ...
Participants who received contingency management were 22% more likely to maintain abstinence at a median of 24 weeks following treatment than those in the ...Missing: opioid cessation
[88]
[PDF] Contingency Management for the Treatment of Substance Use ...
Nov 7, 2023 · CM has three decades of research demonstrating its long-term efficacy for treating a variety of SUDs, including stimulant, opioid, cannabis, ...
[89]
How Portugal is solving its opioid problem
Oct 1, 2018 · The number of HIV diagnoses caused by injection drug use has plummeted by more than 90 percent. Delegates from the United States and other ...Missing: decriminalization HCV
[90]
Drug decriminalisation in Portugal | The BMJ
Sep 10, 2010 · The number of deaths associated with drug use has decreased, from 131 deaths in 2001 to 20 in 2008.
[91]
How Portugal eased its opioid epidemic, while U.S. drug deaths ...
Feb 24, 2024 · The results are striking. Over the last 20 years, Portugal cut drug deaths by 80% and reduced the number of HIV/AIDS and hepatitis cases in ...Missing: HCV | Show results with:HCV
[92]
[PDF] based and one-for-one models for Syringe Exchange Programs
Models of SEPs range from needs-based SEP dispensation policy (least restrictive, where PWIDs receive as many syringes as they need without regard to the ...
[93]
Module 2: Operational Issues - National Harm Reduction Coalition
This manual outlines the process of developing and starting a Syringe Access Program (SAP). It offers best practices rooted in harm reduction.<|separator|>
[94]
[PDF] Syringe Services Programs –A Critical Public Health Intervention
Jul 30, 2019 · Educational materials, including information about: safer injection practices; reversing a drug overdose; HIV prevention, testing, treatment and ...Missing: components | Show results with:components
[95]
[PDF] Program Guidance for Implementing Certain Components of Syringe ...
The purpose of this document is to provide implementation guidance for programs directly funded by CDC interested in implementing new or expanding existing ...
[96]
Syringe Services Programs | HIV.gov
HIV, viral hepatitis, and other blood-borne pathogens can spread through injection drug use if people use needles, syringes, or other injection materials that ...Missing: definition mechanism backflow
[97]
Updates on Syringe Coverage and Service Uptake among Needle ...
There were 342 NSPs and 431 NSPs in 2019 and 2020, respectively, and 324 completed the survey (Bartholomew et al., 2023; Lambdin, Wenger, et al., 2023). Sixty- ...
[98]
Harm reduction in the USA: the research perspective and an archive ...
Jul 26, 2017 · It was not until the late 1980s that syringe exchange programs began at the state and local level in the USA. With funding primarily from state ...
[99]
The History and Significance of Syringe Services - MATTERS Network
Aug 13, 2024 · Needle and syringe services reduce the transmission of many infectious diseases and are not associated with increased substance use nor ...
[100]
[PDF] Effectiveness of Syringe Services Programs: A Systematic Review
Dec 4, 2023 · Syringe exchange programs and harm reduction: new evidence in the wake of the opioid epidemic. J Public Econ. 2022;215:104733. 106. Lambdin ...
[101]
Are needle and syringe programmes associated with a reduction in ...
Dec 26, 2013 · The results of our study suggest there is evidence to support the effectiveness of NSP in reducing HIV transmission, although the quality of ...
[102]
Syringe exchange programs and harm reduction: New evidence in ...
I find that SEP openings decrease HIV rates by up to 18.2 percent. However, I present new evidence that SEPs increase rates of opioid-related mortality.
[103]
Syringe Service Programs for Persons Who Inject Drugs in Urban ...
Dec 11, 2015 · Reducing human immunodeficiency virus (HIV) infection rates in persons who inject drugs (PWID) has been one of the major successes in HIV ...
[104]
Needle exchange programs for the prevention of hepatitis C virus ...
May 17, 2017 · A recently published systematic review with meta-analysis of pharmacy-based NEP demonstrated a 74% reduction in the odds of HCV infection (OR = ...
[105]
[PDF] Are Syringe Exchange Programs Helpful or Harmful? New Evidence ...
Jul 5, 2019 · Most notably, I find that SEPs increase drug-related mortality rates by 11.6 percent and opioid-related mortality rates by 25.4 percent, and ...
[106]
Are Syringe Exchange Programs Helpful or Harmful? New Evidence ...
Jul 25, 2019 · However, I present new evidence that SEPs increase rates of opioid-related mortality and hospitalizations, suggesting that needle exchanges ...
[107]
The effectiveness of abstinence‐based and harm reduction‐based ...
Apr 21, 2024 · The average effect for abstinence‐based interventions compared to treatment‐as‐usual (TAU) service provision was –0.28 SD (95% CI, −0.65, 0.09) ...
[108]
Funding and Delivery of Syringe Services Programs in the United ...
Mar 13, 2024 · A total of 106 699 unintentional drug overdose deaths occurred in the United States in 2021, with a 30% increase from 2019 to 2020 and another ...<|separator|>
[109]
In Boston, complaints of dirty drug needles soar as program ends
Jan 21, 2025 · The number of 311 reports of discarded needles has surged since the city ended a popular needle-buyback program.
[110]
Prioritizing Abstinence-Based Prevention, Regulation, and Recovery ...
Sep 2, 2025 · The integration of abstinence-based regulatory and treatment programs has been successful in reducing tobacco use. In more recent times, there ...
[111]
[PDF] A Century of International Drug Control - Unodc
Indeed, what Karl Marx described as. “the free trade in poison” was such an important source of revenue for Great Powers that they fought for control of opium ...<|control11|><|separator|>
[112]
America's War on Drugs — 50 Years Later
Jun 29, 2021 · Between 1980 and 1997, the number of people locked up for non-violent, drug-related crimes rose from 50,000 to 400,000. The War on Drugs' ...
[113]
Injection Drug Users in the United States, 1979-2002 - JAMA Network
The weighted prevalence of IDU-ever was 1.5%, implying that 3.4 million persons had used injection drugs during their lifetimes. The prevalence of IDU-ever was ...
[114]
Drug Arrests and Injection Drug Deterrence - PMC - PubMed Central
Deterrence-based approaches to reducing drug use seem not to reduce IDU prevalence. Alternative approaches such as harm reduction, which prevents HIV ...
[115]
Prevalence of consumption of illicit drugs and associated factors ...
Apr 29, 2024 · The study found that the prevalence of lifetime and 12-month illicit drug consumption in the population was 2.3% and 0.7%, respectively. The ...
[116]
[PDF] CNB Annual Statistics 2023 - Central Narcotics Bureau
Singapore's drug situation remains under control, but there are worrying trends. The number of drug abusers arrested in 2023 increased by 10% from 2022. Among ...
[117]
Federal funding for syringe exchange in the US: Explaining a long ...
The United States prohibited federal funding for syringe exchange programs for people who inject drugs nearly continuously from 1988 to 2015.
[118]
Congress Plans Historic Federal Funding for Syringe Programs - Filter
Jul 22, 2021 · If passed, this bill would consign to history a federal ban on SSP funding which dates back to 1988. Then-Senator Jesse Helms (R-NC) sponsored ...Missing: Amendment | Show results with:Amendment
[119]
It Took 20 Years For The Government To Pay For An Obvious Way ...
Jan 8, 2016 · But in the final days of December, Congress quietly decided to change the 30-year-old ban on federal funding for needle exchange programs (the ...<|separator|>
[120]
HHS Provides More Than $1.5 Billion in State and Tribal Opioid ...
Sep 22, 2025 · HHS allocated more than $1.5 billion in FY25 continuation funding awards for the State Opioid Response (SOR) and Tribal Opioid Response ...Missing: 2020s SSP
[121]
Strengthening Syringe Services Programs (SSPs) - CDC
Mar 20, 2024 · Strengthening SSPs is a cooperative agreement that aims to build and expand a national network of SSPs, implement and oversee the use of an annual survey of ...
[122]
[PDF] Syringe Services Programs Summary of State Laws
Apr 1, 2025 · referrals, syringe service programs, sharps disposal and medication disposal kits, wound care supplies, medication lock boxes, education,.
[123]
Trump's surgeon general urges red states to support needle ...
Apr 4, 2024 · Former President Trump's surgeon general is advocating for conservative states to back needle exchanges as a strategy to reduce transmission of infectious ...Missing: bans US
[124]
Needle Exchange Programs: Benefits and Challenges - Cato Institute
Jan 15, 2020 · They are endorsed by the Centers for Disease Control and Prevention, the surgeon general of the United States, the World Health Organization, ...
[125]
Executive Summary - Effectiveness of Syringe Services Programs
We also synthesized available evidence on whether outcomes vary by syringe exchange model (needs-based versus 1-for-1) or presence/absence of program components ...
[126]
Implementation Gaps in US Syringe Services Programs, 2022
Jul 23, 2025 · This cross-sectional study examines implementation gaps in syringe service programs by US Census division, urbanicity, and level of need.<|separator|>
[127]
Cost-effectiveness of syringe service programs, medications for ...
SSP had the largest incremental cost savings per HCV case avoided per 100 opioid IDUs compared with the no intervention strategy. Public payers adopting the SSP ...
[128]
Is your syringe services program cost-saving to society? A ...
Dec 7, 2021 · We present a method for estimating a threshold value for the number of HIV infections prevented above which the program will be cost-saving to society.
[129]
Cost-effectiveness of syringe service programs
Jan 12, 2021 · The analysis was done to assist local community and public payers in decision making regarding adoption of harm-reduction strategies to prevent.